Atlas Trials

Cabaletta Bio

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Cabaletta Bio

RecordFirmDate
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis (NCT07006805)Cabaletta Bio2026-06-01
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis (NCT06359041)Cabaletta Bio2024-12-17
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis (NCT06328777)Cabaletta Bio2024-07-02
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus (NCT06121297)Cabaletta Bio2024-02-16
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (NCT06154252)Cabaletta Bio2023-12-20
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis (NCT05451212)Cabaletta Bio2022-11-23
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) (NCT04422912)Cabaletta Bio2020-09-29

Track Cabaletta Bio automatically

Every clearance here is in the API, with alerts when new ones post.